Synergistic combination of PDE inhibitors and adenylate...

Details Synergistic combination of PDE inhibitors and adenylate... Synergistic combination of PDE inhibitors and adenylate...

1999-08-27

2001-12-25

Krass, Frederick (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C514S520000, C514S521000, C514S523000

Reexamination Certificate

active

06333354

ABSTRACT:

FIELD OF APPLICATION OF THE INVENTION
The invention relates to the combination of certain known active compounds for therapeutic purposes.
KNOWN TECHNICAL BACKGROUND
The substances used in the combination according to the invention are known active compounds from the class consisting of the PDE inhibitors and from the class consisting of the adenylate cyclase agonists and the guanylate cyclase agonists. Their combined use in the sense according to the invention for therapeutic purposes has not yet been described in the prior art.


REFERENCES:
patent: 4721729 (1988-01-01), Skuballa et al.
patent: 5376371 (1994-12-01), Bomabardelli
patent: 6013827 (2000-11-01), Bordas-Nagy
patent: 96/06612 (1996-03-01), None
patent: WO-96/06612-A1 (1996-03-01), None
Riva et al., “Iloprost Inhibits Neutrophil-Induced Lung injury and Neutrophil Adherence to Endothelial Monolayers” Am J Respir Cell Mol Biol, 3 (4). 1990. 301-310.*
Buerke et al.: “Synergistic platelet inhibitory effect of the phosphodiesterase inhibitor piroximone and iloprost:” Prostaglandins in the Cardiovascular System, 1992, 37/suppl. (71-77).*
O'Grady et al. “A chemically stable analot 9-beta methylcarbacyclin with similar effects to epoprostenol prostacyclin prostaglandin in I-2 in man” Br J Clin Pharmacol, 18(6). 1984 (921-934).*
Crutchley et al. “Effects of Prostacyclin Analogs on the Synthesis of Tissue Factor, Tumor Necrosis Facotr-alpha and Interleukin-1beta in Human Monocytic THP-1 Cells”, J Pharmacol and Experimental Therapeutics, 271 (1). 1994. 446-451.*
Crutchley et al. “Prostacyclin Analogues Inhibit Tissue Factor Expression in the Human Monocytic Cell Line THP-1 Via a Cyclic AMP-Dependent Mechanism” Arterioscler. Thromb, 12(6), 1992. 664-670.*
Turner et al.,Br. J. Pharmacol.,“Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anaesthetized guinea-pig”, (1994), 111, pp. 1198-1204.
Buerke et al.,Prostaglandins in the Cardiovascular System,“Synergistic Platelet Inhibitory Effect of the Phosphodiesterase Inhibitor Piroximone and Iloprost”, 1992 Birkhäuser Verlag Basel, pp. 71-77.
O'Grady et al.: “A Chemically Stable Analog 9-Beta Methylcarbacyclin With Similar Effects to Epoprostenol Prostacyclin Prostaglandin I-2 in Man”, Br J Clin Pharmacol, 18 (6), 1984, 921-934.

Affiliated with

Also associated with

Rating

Synergistic combination of PDE inhibitors and adenylate... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synergistic combination of PDE inhibitors and adenylate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic combination of PDE inhibitors and adenylate... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2598608